After months of NCPA and other pharmacy organizations advocating for such a change, the FDA on Wednesday revised the EUA for Paxlovid, authorizing state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing. “The FDA recognizes the important role pharmacists have played and continue to play in combatting this pandemic,” Patrizia Cavazzoni, director for the FDA’s Center for Drug Evaluation and Research, said in a press release. “Since Paxlovid must be taken within five days after symptoms begin, authorizing state-licensed pharmacists to prescribe Paxlovid could expand access to timely treatment for some patients who are eligible to receive this drug for the treatment of COVID-19.” This action allows pharmacists to prescribe Paxlovid with certain limitations as described in the FDA press release. Read the FDA press release here.
NCPA
